A 35-year-old woman from Delhi with known chronic hepatitis B (HBeAg-positive, HBV DNA 2.5 × 10^6 IU/mL) presents with acute jaundice, ALT 3200 IU/L, AST 2800 IU/L, and INR 1.4. Anti-HDV is positive; anti-HAV IgM is negative. She is alert, oriented, and has no ascites. Albumin is 3.2 g/dL. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: Acute HDV Superinfection on Chronic HBV **Key Point:** Anti-HDV positivity in a chronic HBsAg-positive patient indicates hepatitis D (delta) virus superinfection. HDV is a defective RNA virus requiring HBsAg for assembly; superinfection on chronic HBV causes more severe acute hepatitis than HBV alone, with higher rates of fulminant hepatic failure and cirrhosis progression. **High-Yield:** HDV superinfection on chronic HBV carries a mortality risk of 2–20% in the acute phase. Distinguishing severe acute hepatitis from fulminant hepatic failure (FHF) is critical for management decisions. ## Assessment of Severity | Parameter | Finding | Significance | |-----------|---------|---------------| | INR | 1.4 | Mildly elevated; synthetic function partially preserved | | Albumin | 3.2 g/dL | Low-normal; early hepatic dysfunction | | Mental status | Alert, oriented | No encephalopathy | | ALT/AST | >3000 IU/L | Severe acute hepatitis | | Ascites | Absent | No portal hypertension yet | **Clinical Pearl:** FHF requires INR >1.5 AND hepatic encephalopathy. This patient meets neither criterion — she has severe acute hepatitis, not FHF. Urgent transplant evaluation (Option A) is premature at this stage and is reserved for patients with established FHF or rapidly deteriorating synthetic function. ## Why Each Option Is Incorrect - **Option A (Urgent transplant evaluation):** Transplant evaluation is indicated for FHF (INR >1.5 + encephalopathy) or rapidly progressive decompensation. This patient is alert with INR 1.4 — premature referral bypasses potentially effective medical management. - **Option B (Tenofovir + lamivudine + immediate interferon-alpha):** Interferon-alpha is contraindicated in acute severe hepatitis and decompensated liver disease due to risk of precipitating hepatic decompensation (EASL HBV Guidelines 2017; AASLD 2018). Dual nucleos(t)ide therapy without interferon is appropriate once the patient stabilizes. - **Option C (High-dose corticosteroids):** Corticosteroids are contraindicated in viral hepatitis; they suppress immune clearance, promote viral replication, and worsen outcomes. This is a well-established contraindication (Harrison's Principles of Internal Medicine, 21st ed.). ## Management Strategy ``` Acute HDV superinfection on chronic HBV ↓ Is FHF present? (INR >1.5 + encephalopathy) NO → Admit to HDU/ICU for supportive care ↓ Supportive care: fluids, nutrition, coagulopathy management ↓ Monitor INR, albumin, mental status q12–24h ↓ Stabilization achieved? → Start tenofovir (antiviral for HBV) ↓ Consider pegylated interferon-alpha for HDV once stable ↓ If deterioration → Escalate to transplant evaluation YES → Urgent transplant evaluation ``` ## Rationale for Option D 1. **Admission and close monitoring** — Severe acute hepatitis with early coagulopathy carries risk of rapid decompensation; HDU/ICU monitoring is essential (EASL 2017). 2. **Supportive care first** — Stabilize fluid balance, electrolytes, and coagulation before initiating antivirals. 3. **Antiviral initiation with tenofovir** — AASLD and EASL guidelines support early antiviral therapy with tenofovir disoproxil fumarate in acute severe HBV (and HBV/HDV) to reduce viral load and limit ongoing hepatocyte injury. Initiation after initial stabilization (rather than in the first hours of presentation) is a reasonable and guideline-consistent approach. 4. **Interferon-alpha for HDV** — Pegylated interferon-alpha remains the only approved therapy for HDV (EASL 2017); however, it is contraindicated in the acute decompensated phase and should only be considered once the patient has clinically stabilized. It is NOT indicated if FHF develops. 5. **Transplant evaluation held in reserve** — Escalate if INR rises >1.5, encephalopathy develops, or clinical trajectory worsens despite 48–72 hours of optimal medical management. **Warning (EASL/AASLD):** Interferon-alpha must NOT be started during acute severe hepatitis or decompensated liver disease — it can precipitate acute-on-chronic liver failure. Nucleos(t)ide analogues (tenofovir) are safe and preferred in this phase. *References: EASL Clinical Practice Guidelines on Hepatitis D, J Hepatol 2023; AASLD HBV Guidance 2018; Harrison's Principles of Internal Medicine, 21st ed.*